ORIC Pharmaceuticals has promising early data for ORIC-944 and ORIC-114, but remains in very early clinical stages. See why I ...

We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) stands ...

The last time I wrote an article on ORIC Pharmaceuticals (NASDAQ:ORIC) it was with respect to a Seeking Alpha article entitled "ORIC Pharma: ORIC-114 Advancement To Phase 1b Expansion Study Could ...

ORIC Pharmaceuticals, Inc. announced the presentation of preclinical data on ORIC-944, a selective allosteric inhibitor of PRC2, at the 2025 American Association for Cancer Research Annual Meeting ...

ORIC Pharmaceuticals SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing ...

In preclinical prostate cancer models, ORIC-944 demonstrated robust inhibition of PRC2, enhanced luminal cell state, and increased androgen receptor (AR) signaling. Analysis of chromatin revealed ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...